Index. Note: Page numbers of article titles are in boldface type.

Size: px

Start display at page:

Download "Index. Note: Page numbers of article titles are in boldface type."

Anthony Barton
5 years ago
Views:

1 Urol Clin N Am 31 (2004) Index Note: Page numbers of article titles are in boldface type. A Acinar proliferation, atypical small, as markers for risk of development of prostate cancer, 229 Acupuncture, for treatment of erectile dysfunction, Alcohol consumption, as risk factor for adult renal cell carcinoma, 242 moderation of, for prevention of prostate cancer, Alendrolate, therapy with, to prevent bone loss in prostate cancer patients, Alternative medicine, for treatment of chemotherapy effects in prostate cancer patients, in prevention and treatment of erectile dysfunction acupuncture, dietary supplements, , Amifostine (WR-2721), reducing complications of radiotherapy for localized prostate cancer in men with, Anabolic steroids, for prevention and treatment of erectile dysfunction, androstenedione, dehydroepiandrosterone (DHEA), Androgen deprivation therapy, for prostate cancer treatment, bisphosphonate therapy to prevent bone loss due to, bone evaluations to perform before, minimizing bone loss due to, osteoporosis in men due to, Androstenedione, for prevention and treatment of erectile dysfunction, Angiogenesis, markers of, as surrogate endpoints in prostate cancer prevention, 231 Antiemetic agents, for treatment of chemotherapy effects in prostate cancer patients, Antihypertensive drugs, as risk factor for adult renal cell carcinoma, 241 Antioxidants, as a protective factor against urologic cancers, 282 Apolipoprotein A-I, as marker for coronary heart disease, Apolipoprotein B, as marker for coronary heart disease, Apoptosis, markers of, as surrogate endpoints in prostate cancer prevention, Arginine, L-, for prevention and treatment of erectile dysfunction, Aspirin, as risk factor for adult renal cell carcinoma, Atypical small acinar proliferation, as marker of risk for development of prostate cancer, 229 Avena sativa (oats), for prevention and treatment of erectile dysfunction, 266 B Biomarkers. See Markers, molecular. Bisphosphonate therapy, in prostate cancer patients undergoing androgen deprivation therapy, for bone loss, for bone metastases, for prevention of bone metastases, Bladder cancer, preventive medicine and, potential role of cyclooxygenase-2 inhibitors in, 215 Body-mass index, patient awareness of, in prevention of prostate cancer, Bone loss. See also Osteoporosis., in men with prostate cancer, reasons for increased risk, Bone metastases, from prostate cancer, bisphosphonate therapy and, in patients with, /04/$ - see front matter Ó 2004 Elsevier Inc. All rights reserved. doi: /s (04)00045-x

2 380 Index / Urol Clin N Am 31 (2004) Bone metastases (continued ) prevention of bone loss with, other drugs for, Bone mineral density, effect of prostate cancer treatment on, imaging methods for determination of, low, risk factor for osteoporosis, 322 Brachytherapy, for localized prostate cancer, complications associated with, 356 patient selection for, reducing risk of complications, using drugs to reduce complications, C C-reactive protein, as marker for coronary heart disease, 201 Calcium supplements, to minimize bone loss in prostate cancer patients, Calcium, coronary, as marker for coronary heart disease, 203 Cancer, prostate. See Prostate cancer. renal. See Renal cell carcinoma. Carboplatin, toxicity of, in prostate cancer treatment, 370 Cardiovascular disease, as risk factor for adult renal cell carcinoma, 242 correlation with prostate cancer, background, recent studies of, patient awareness of risk of, in prevention of prevention of, impact on men s health, , most common markers of, potential and emerging markers of, Cardiovascular health, and prevention of erectile dysfunction, patient awareness of, in prevention of prostate cancer, Cell-cycle regulators, markers of, as surrogate endpoints in prostate cancer prevention, Chemo-hormonal therapy, toxicity of, in prostate cancer treatment, 372 Chemoprevention, of prostate cancer, studies of potential markers for, atypical intraepithelial lesions, molecular markers as surrogate endpoints, Chemotherapy, for prostate cancer, prevention and management of complications of, common adverse effects, overview, patient-specific factors, 369 prevention of toxicity, toxicity of specific regimens, chemo-hormonal therapy, 372 docetaxel, 371 docetaxel plus estramustine, 371 etoposide and estramustine, 372 mitoxantrone plus prednisone, paclitaxel plus estramustine, three-drug combinations, 372 Cholesterol, non-high-density lipoprotein, as marker for coronary heart disease, Cholesterol, total serum, as marker for heart disease, correlation between prostate cancer and, patient awareness of, in prevention of prostate cancer, reduction of through lifestyle changes, effect on erectile dysfunction, Clodronate, therapy with, to prevent bone loss in prostate cancer patients, 338, 342, 344, 346 Coffee consumption, as risk factor for adult renal cell carcinoma, 242 Complementary medicine, for treatment of chemotherapy effects in prostate cancer patients, in prevention and treatment of erectile dysfunction acupuncture, dietary supplements, , Complications, associated with radiotherapy for localized prostate cancer, Computed tomography, quantitative (QCT), screening for osteoporosis with, 323, 324, 327 Computer-assisted image analysis, malignancy-associated changes on, as markers in prevention of prostate cancer, Conformal radiotherapy, three-dimensional, for localized prostate cancer, reducing complications of,

3 Index / Urol Clin N Am 31 (2004) Coronary heart disease, correlation with prostate cancer, background, recent studies of, family history of, as risk factor, patient awareness of risk of, in prevention of prevention of, impact on men s health, , most common markers of, potential and emerging markers of, Cyclooxygenase-2 (COX-2) inhibitors, potential role of in prevention of urologic conditions, in bladder cancer, 215 in kidney cancer, 215 in prostate cancer, Cyclophosphamide, toxicity of, in prostate cancer treatment, 368, 369, 370 D Damiana (Turnera diffusa), for prevention and treatment of erectile dysfunction, Dehydroepiandrosterone (DHEA), for prevention and treatment of erectile dysfunction, Dexamethasone, toxicity of, in prostate cancer treatment, 368 Diabetes mellitus, as risk factor for adult renal cell carcinoma, 242 complications of radiotherapy for localized prostate cancer in men with, 361 patient awareness of risk of, in prevention of Diet, lifestyle changes for prevention of prostate cancer, fiber in, fish in, for weight loss, fruits and vegetables in, 302 soy and other plant estrogens in, unsaturated fats in, low-fat, as a protective factor against urologic cancers, 282 Dietary supplements, prevention and treatment of erectile dysfunction using, , anabolic steroids, Avena sativa (oats), 266 damiana, ginko biloba, 262 impact of and regulations for, interactions with drugs and procedures, 252 Korean red ginseng, L-arginine, placebo effects of, quality control, 251 Tribulus terrestris, 266 yohimbine, 264 zinc, Docetaxel, toxicity of, in prostate cancer treatment, 368, 370, 371 in regimen with estramustine, 371 Doxorubicin, toxicity of, in prostate cancer treatment, 368, 369, 370, 372 Dual-energy x-ray absorptiometry (DEXA), screening for osteoporosis with, 323, E Endothelin-1, for bone complications related to prostate cancer, 347 Epithelial lesions, atypical, of prostate, as markers for risk of development of prostate cancer, Erectile dysfunction, prevention and treatment of, , acupuncture for, combining prescription drugs and supplements, lifestyle changes for, using dietary supplements, , anabolic steroids, Avena sativa (oats), 266 damiana, ginko biloba, 262 impact of and regulations for, interactions with drugs and procedures, 252 Korean red ginseng, L-arginine, placebo effects of, quality control, 251 Tribulus terrestris, 266 yohimbine, 264 zinc, Estramustine, toxicity of, in prostate cancer treatment, 368, 370 in chemo-hormonal therapy, 372 in three-drug combinations, 372 with docetaxel, 371 with etoposide, 372 with paclitaxel,

4 382 Index / Urol Clin N Am 31 (2004) Estrogen, dietary soy, for prevention of prostate cancer, Etidronate, therapy with, to prevent bone loss in prostate cancer patients, Etoposide, toxicity of, in prostate cancer treatment, 368, 369, 370 in regimen with estramustine, 372 in three-drug combinations, 372 Exercise, as a protective factor against urologic cancers, recommendations for prevention of prostate cancer, External beam radiotherapy, for localized prostate cancer, common complications due to, impotency due to, improving accuracy of delivery of, intensity-modulated, 358 patient selection for, reducing complications associated with, three-dimensional conformal, using drugs to reduce complications, F Fats, unsaturated, in diet, for prevention of prostate cancer, Fertility, effects of obesity on, 277 Fiber, viscous (soluble), in diet, for prevention of prostate cancer, Fish, in diet, for prevention of prostate cancer, Fruits, in diet, for prevention of prostate cancer, 302 G Ginko biloba, for prevention and treatment of erectile dysfunction, 262 Ginseng, Korean red, for prevention and treatment of erectile dysfunction, Growth factors, for prevention and treatment of toxicity during prostate cancer treatment, H Heart disease, correlation with prostate cancer, patient awareness of risk of, in prevention of prevention of coronary, impact on men s health, , most common markers of, potential and emerging markers of, Heel ultrasound, screening for osteoporosis with, 324, 327 High-density lipoprotein (HDL), as marker for heart disease, patient awareness of, in prevention of prostate cancer, Homocysteine, as marker for coronary heart disease, Hormonal factors, as risk factor for adult renal cell carcinoma, Hormonal therapy, toxicity of, in prostate cancer treatment, 372 Hypertension, as risk factor for adult renal cell carcinoma, as risk factor for heart disease, patient awareness of, as risk for prostate cancer, 291 I Image analysis, computer-assisted, malignancy-associated changes on, as markers in prevention of prostate cancer, Imaging, in screening for osteoporosis, Impotence, radiation-induced, in men with localized prostate cancer, Incontinence, stress urinary, obesity-related, 276 Inflammatory bowel disease, complications of radiotherapy for localized prostate cancer in men with, Intensity-modulated radiotherapy, for localized prostate cancer, reducing complications of, 358 K Ketoconazole, toxicity of, in prostate cancer treatment, 370, 372 Kidney cancer. See also Renal cell carcinoma., preventive medicine and, potential role of cyclooxygenase-2 inhibitors in, 215 Kidney disease, pre-existing, as risk factor for adult renal cell carcinoma,

5 Index / Urol Clin N Am 31 (2004) Kidney injury, as risk factor for adult renal cell carcinoma, 239 Kidney stones, as risk factor for adult renal cell carcinoma, 238 Korean red ginseng, for prevention and treatment of erectile dysfunction, L L-Arginine, for prevention and treatment of erectile dysfunction, Lifestyle recommendations, to prevent and treat erectile dysfunction, to prevent prostate cancer, , Lipid profile, patient awareness of, in prevention of Lipoproteins, high-density (HDL), as marker for heart disease, patient awareness of, in prevention of lipoprotein (a), as marker for coronary heart disease, low-density (LDL), as marker for heart disease, Low-fat diets, as a protective factor against urologic cancers, 282 Lower urinary tract symptoms, obesity-related, Luteinizing hormone-releasing hormone, for prostate cancer treatment, bone loss due to, M Malignancy-associated changes, on computer-assisted image analysis, as markers of prostate cancer, Markers, molecular, as surrogate endpoints in prostate cancer prevention, new frontiers in, 232 of angiogenesis, 231 of cell-cycle regulators, proliferation, and apoptosis, on computer-assisted image analysis of malignancy-associated changes, serum, for cardiovascular disease, , apolipoprotein A-I, apolipoprotein B, C-reactive protein, 201 coronary calcium scoring, 203 homocysteine, lipoprotein (a), non-high-density lipoprotein cholesterol, total cholesterol, Medications, as risk factor for adult renal cell carcinoma, analgesics, antihypertensive drugs, 241 Metastases, bone, from prostate cancer, bisphosphonate therapy and, in patients with, prevention of bone loss with, other drugs for, Mitoxantrone, toxicity of, in prostate cancer treatment, 368 in regimen with prednisone, Molecular markers, as surrogate endpoints in prostate cancer prevention, new frontiers in, 232 of angiogenesis, 231 of cell-cycle regulators, proliferation, and apoptosis, on computer-assisted image analysis of malignancy-associated changes, Morbid obesity. See also Obesity., complications of radiotherapy for localized prostate cancer in men with, 361 Mucositis, prevention and treatment of during prostate cancer treatment, 374 N Nausea and vomiting, prevention and treatment of during prostate cancer treatment, 374 O Oats (Avena sativa), for prevention and treatment of erectile dysfunction, 266 Obesity, as risk factor for adult renal cell carcinoma, 238 complications of radiotherapy for localized prostate cancer in men with, 361 impact of, in urology, benign urologic disease and, erectile dysfunction, 277 fertility, 277 lower urinary tract symptoms, renal diseases, 278

6 384 Index / Urol Clin N Am 31 (2004) Obesity (continued ) stone formation, stress urinary incontinence, 276 malignant urologic disease and, bladder cancer, 281 kidney cancer, prostate cancer, testicular cancer, 281 protective factors, 282 antioxidants, 282 exercise and weight loss, low-fat diets and dietary factors, 282 vitamin D, 282 technical factors in surgery on, patient awareness of risks of, in prevention of prostate cancer, Occupational exposures, as risk factor for adult renal cell carcinoma, Online imaging, to reduce toxicity of radiotherapy for localized prostate cancer, Osteoporosis, male, caused by prostate cancer treatment, definition and diagnosis of, 313, 322 interpreting imaging tests, other tests for, prevention of, prostate cancer-associated, clinical impact of, etiology and epidemiology, treatment options, risk factors for, 324 P Paclitaxel, toxicity of, in prostate cancer treatment, 368, 370 in regimen with estramustine, in three-drug combinations, 372 Pamidronate, therapy with, to prevent bone loss in prostate cancer patients, Paracetamol, as risk factor for adult renal cell carcinoma, Parathyroid hormone-releasing peptide, for bone complications related to prostate cancer, Pathologic markers. See Markers. Patient selection, to reduce complications of radiotherapy for localized prostate cancer, Phenacetin, as risk factor for adult renal cell carcinoma, Physical activity, recommendations for prevention of prostate cancer, Placebo effect, with supplements for erectile dysfunction, Prednisone, toxicity of, in prostate cancer treatment, 368 in regimen with mitoxantrone, Prescription drugs, combined with supplements for prevention and treatment of erectile dysfunction, Preventive medicine, in urology, coronary heart disease and, correlation with prostate cancer, prevention of, impact on men s health, , most common markers of, potential and emerging markers of, cyclooxygenase-2 and 5a-reductase in, erectile dysfunction, prevention and treatment of, , obesity, impact of, osteoporosis, impact in men treated for prostate cancer, prevalence, risks, and diagnosis of, prostate cancer, bone loss and bone metastases in, chemoprevention studies, potential markers for, chemotherapy for, preventing and managing complications of, correlation with coronary heart disease, lifestyle recommendations to prevent, , osteoporosis in men treated for, radiotherapy for localized, reducing toxicity of, screening for, current recommendations, renal cell carcinoma, risk factors for, in adults, Proliferation, markers of, as surrogate endpoints in prostate cancer prevention, Prostate cancer, bone loss and bone metastases in, bisphosphonate therapy for,

7 Index / Urol Clin N Am 31 (2004) evaluations to perform before beginning androgen deprivation therapy, other drugs for, reasons for risk of bone loss in, steps to minimize bone loss due to androgen deprivation therapy, chemoprevention studies, potential markers for, atypical intraepithelial lesions, molecular markers as surrogate endpoints, chemotherapy for, prevention and management of complications of, common adverse effects, overview, patient-specific factors, 369 prevention of toxicity, toxicity of specific regimens, correlation with coronary heart disease, background, recent studies of, lifestyle recommendations for prevention of, , osteoporosis in men treated for, clinical impact of, etiology and epidemiology, treatment options, potential role of cyclooxygenase-2 inhibitors in, radiotherapy for localized, reducing toxicity of, common complications due to, patient selection for, reducing complications due to, using drugs to reduce complications, screening for, disease prevalence, 219 early detection, effective tests for, Prostate size, complications of radiotherapy for localized prostate cancer in men with large, 361 Prostate-specific antigen (PSA), in prostate cancer screening, Prostatic intraepithelial neoplasia, as marker of risk for development of prostate cancer, Protective factors, against obesity-related urologic cancers, antioxidants, 282 exercise and weight loss, low-fat diets and dietary factors, 282 vitamin D, 282 Q Quality control, for dietary supplements used for preventing and treating erectile dysfunction, 251- Quantitative computed tomography (QCT), screening for osteoporosis with, 323, 324, 327 R Radiotherapy, in men with localized prostate cancer, reducing toxicity of, common complications of, impotence, with brachytherapy, 356 with external-beam radiotherapy, reducing complications of, patient selection for, using drugs to, with brachytherapy, 359 with external-beam radiotherapy, Receptor activator of nuclear factor kb ligand (RANKL), for bone complications related to prostate cancer, Reductase inhibitors, 5a-, potential role of in prevention of urologic conditions, Renal cell carcinoma, adult, risk factors for, alcohol consumption, 242 coffee consumption, 242 hypertension, medical history, 242 medication, analgesics, antihypertensive drugs, 241 metabolic diseases, 242 obesity, 238 occupational exposure, pre-existing kidney disease, kidney injury, 239 kidney stones, 238 urinary tract infection, 238 reproductive and hormonal factors, socioeconomic status, 242 tobacco, 238 Renal diseases, effects of obesity on, 278 Reproductive factors, as risk factor for adult renal cell carcinoma,

8 386 Index / Urol Clin N Am 31 (2004) Resistance exercises, recommendations for prevention of prostate cancer, Risk assessment, for cardiovascular disease, in urology patients, , Risk factors, for adult renal cell carcinoma, Risk markers. See Markers, serum. S Screening, for prostate cancer, screening for, disease prevalence, 219 early detection, effective tests for, Sildenafil (Viagra), interactions with dietary supplements used for erectile dysfunction, Smoking, as risk factor for heart disease, Smoking cessation, recommendations for prevention of prostate cancer, Socioeconomic status, as risk factor for adult renal cell carcinoma, 242 Soy, in diet, for prevention of prostate cancer, Steroids, anabolic, for prevention and treatment of erectile dysfunction, androstenedione, dehydroepiandrosterone (DHEA), Stone formation, effects of obesity on, 277 Stress urinary incontinence, obesity-related, 276 Supplements. See Dietary supplements. Surgical procedures, interactions of dietary supplements used for erectile dysfunction and, 252 urologic, in obese patients, technical factors affecting outcome, T Thiazide, as risk factor for adult renal cell carcinoma, 241 Three-dimensional conformal radiotherapy, for localized prostate cancer, reducing complications of, Thyroid diseases, as risk factor for adult renal cell carcinoma, 242 Tobacco use. See also Smoking.,as risk factor for adult renal cell carcinoma, 238 Total cholesterol. See Cholesterol, total serum. Toxicity, of chemotherapy for prostate cancer, of radiotherapy for localized prostate cancer, Tribulus terrestris,for prevention and treatment of erectile dysfunction, 266 Triglycerides, as marker for heart disease, U Ultrasound, heel, screening for osteoporosis with, 324, 327 Urinary incontinence, stress, obesity-related, 276 Urinary tract infection, as risk factor for adult renal cell carcinoma, 238 Urinary tract symptoms, lower, obesity-related, Urologic diseases, obesity-related, benign, malignant, protective factors, Urology, preventive medicine in. See Preventive medicine. V Vegetables, in diet, for prevention of prostate cancer, 302 Viagra, interactions with dietary supplements used for erectile dysfunction, Vinblastine, toxicity of, in prostate cancer treatment, 368, 370 Vinorelbine, toxicity of, in prostate cancer treatment, 368, 370 Vitamin D, as a protective factor against urologic cancers, 282 Vitamin D supplements, to minimize bone loss in prostate cancer patients, Vomiting, prevention and treatment of during prostate cancer treatment, 374 W Waist-to-hip ratio, patient awareness of, in prevention of prostate cancer,

9 Index / Urol Clin N Am 31 (2004) Weight, patient awareness of healthy, in prevention of prostate cancer, Weight loss, as a protective factor against urologic cancers, lifestyle changes for, in prevention of prostate cancer, Weight-bearing exercises, recommendations for prevention of prostate cancer, WR-2721 (amifostine), reducing complications of radiotherapy for localized prostate cancer in men with, Y Yohimbine, for prevention and treatment of erectile dysfunction, 264 Z Zinc supplements, for prevention and treatment of erectile dysfunction, Zolendronic acid, for osteoporosis in men treated for prostate cancer, 319 therapy with, to prevent bone loss in prostate cancer patients,

Subject Index. Androgen antiandrogen therapy, see Hormone ablation therapy, prostate cancer synthesis and metabolism 49

Subject Index. Androgen antiandrogen therapy, see Hormone ablation therapy, prostate cancer synthesis and metabolism 49 OOOOOOOOOOOOOOOOOOOOOOOOOOOOOO Subject Index Androgen antiandrogen therapy, see Hormone ablation therapy, synthesis and metabolism 49 Bacillus Calmette-Guérin adjunct therapy with transurethral resection